普伐他汀治疗肝酶升高的急性冠脉综合征38例的安全性

目的：观察肝酶升高的急性冠脉综合征(ACS)病人应用普伐他汀的安全性。方法：ACS病人120例,根据入院时血清丙氨酸转氨酶(ALT)的情况分为肝酶升高组(ALT＞40 IU·L~(-1))38例和肝酶正常组(ALT≤40IU·L~(-1))82例。2组病人在入院时均接受抗血小板、抗凝、肾上腺素β受体阻滞药、血管紧张肽转换酶抑制药、硝酸酯等药物的同时给予普伐他汀20 mg,po,qd,分别于给药d10,d30后复查肝功能,比较用药前后ALT的变化,计算2组病人用药后肝损伤所占比率。结果：普伐他汀治疗10 d,30d后,肝酶升高组与肝酶正常组比较,肝损伤发生率无明显差异(5% vs 2%,P＞0．05和3% vs 2%,P＞0．05)。普伐他汀治疗1mo后肝酶升高组肝功能好转(45±s 15)IU·L~(-1) vs (66±19)IU·L~(-1),P＜0．01]。结论：肝酶升高的急性冠脉综合征早期应用普伐他汀安全,不增加肝毒性。

Safety of pravastatin in 38 acute coronary syndrome patients with elevated liver enzyme

AIM:To investigate the safety of pravastatin in acute coronary syndrome(ACS)patients with elevated liver enzyme.METHODS:One hundred and twenty ACS patients were divided into elevated liv- er enzyme group(ALT＞40 IU·L~(-1),38 patients)and normal group(ALT≤40 IU·L~(-1),82 patients).All patients were administered with 20mg pravastatin per day,the eftects of pravastatin on liver biochemistries and tissue damage were assessed by detecting ALT levels 10d and 30d after the administrations.RESULTS:There were no significant differences in incidences of liver injury 10 d and 30 d after administration in the comparisons between two groups(5%vs 2%,P＞0.05;3% vs 2%,P＞0.05).Liver function in elevated liver enzyme group had been improved 30d after administration with pravastatin((45+s15)IU·L~(-1)vs(66±19)IU·L~(-1), P＜0.01).CONCLUTION:Early adimistrating pravastatin in ACS patients with elevated baseline liver en- zyme is safe and does not increase hepatotoxicity.